Roche files T-DM1 for HER2-positive breast cancer in US
This article was originally published in Scrip
Executive Summary
Roche (Genentech) has filed for accelerated approval in the US for its antibody-drug conjugate trastuzumab-DM1 (T-DM1), for patients with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.